Morphea, which is also known as localized scleroderma, is a disorder caused by excessive collagen deposition and characterized by the thickening and hardening of the skin. Unlike systemic sclerosis, morphea lacks features such as Raynaud phenomenon, joint involvement, sclerodactyly, and constitutional symptoms. It may be associated with drug use and is occasionally found together with other autoimmune diseases. In this article, we report a 60-year-old woman who was admitted to our outpatient clinic due to HLA B27 + ankylosing spondylitis with axial involvement and morphea. Her disease was able to be managed with exercise and non-steroidal anti- inflammatory drugs, however, a 10¥7 cm diameter atrophic lesion of medium hardness was identified on her left shoulder. The histopathology of the lesion was compatible with morphea, and improved with topical steroid treatment. Although the concomitance of autoimmune diseases is frequent, there is no coexistence of morphea with ankylosing spondylitis in the literature, except a case who was considered to be associated with the adalimumab use. Despite limited data, however, common autoimmune pathogenesis may be seen in association with ankylosing spondylitis and morphea.
1. Ramírez J, Hernández MV, Galve J, Cañete JD, Sanmartí R. Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol 2012;22:6024.
2. Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol 2008;20:6017.
3. Kreuter A. Localized scleroderma. Dermatol Ther 2012;25:13547.
4. Leitenberger JJ, Cayce RL, Haley RW, Adams- Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009;145:54550.
5. Ramonda R, Lo Nigro A, Campana C, Frallonardo P, Alaibac M, Punzi L. An unusual association between erosive hand osteoarthritis and morphea. Joint Bone Spine 2011;78:5323.
6. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011;64:21728.
7. Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 2008;59:1259.
8. Stewart FA, Gavino AC, Elewski BE. New side effect of TNF-alpha inhibitors: morphea. Skinmed 2013;11:5960.
9. Alimova E, Farhi D, Plantier F, Carlotti A, Gorin I, Mouthon L, et al. Morphoea (localized scleroderma): baseline body surface involvement and antinuclear antibody may have a prognostic value. Clin Exp Dermatol 2009;34:e4912.
10. Ouédraogo DD, Palazzo E, Nlomé-Nzé M, Somogyi- Demerjian N, Meyer O. Ankylosing spondylitis and systemic sclerosis: a rare combination. Joint Bone Spine 2009;76:2902.
11. Kayser C, Alvarenga MC, Neves AS, Gerbase-De Lima M, Andrade LE. Severe ankylosing spondylitis and diffuse systemic sclerosis: case report of a genetic trap. Scand J Rheumatol 2005;34:1457.
12. Soledade CS, Sampaio-Barros PD, Samara AM, Marques- Neto JF. Unusual association of systemic sclerosis and ankylosing spondylitis. Clin Rheumatol 2005;24:6524.
13. Omair MA, Johnson SR. Inflammatory arthritis, sacroiliitis, and morphea: evidence of a systemic inflammatory disease. Case Rep Rheumatol 2013;2013:347694.
14. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford) 2005;44:2749.
15. Kurzinski K, Torok KS. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 2011;55:15764.
16. Zambrano-Zaragoza JF, Agraz-Cibrian JM, González- Reyes C, Durán-Avelar Mde J, Vibanco-Pérez N. Ankylosing spondylitis: from cells to genes. Int J Inflam 2013;2013:501653.
17. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2006;45:61420.